Nitroglycerin inhibits the development of morphine tolerance and dependence in rats

Pharmacology Biochemistry and Behavior

Volumn 74, Issue 3, 2003, Pages 551-557

  Cha, Edward Y ^a   Moulédous, Lionel ^a   Harris, J Robin ^a   Weech, Mark A ^a   Gutstein, Howard B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Modulation; Naloxone; Narcotic; NMDA receptor; Opioids; Withdrawal

Indexed keywords

GLYCERYL TRINITRATE; MORPHINE; NALOXONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; DRUG WITHDRAWAL; MALE; MORPHINE ADDICTION; MORPHINE TOLERANCE; NONHUMAN; PRIORITY JOURNAL; RAT; TAIL FLICK TEST; WITHDRAWAL SYNDROME;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; INFUSION PUMPS, IMPLANTABLE; MALE; MORPHINE DEPENDENCE; NITROGLYCERIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0037307140     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)01036-5     Document Type: Article

References (30)

1. Blasig J., Herz A. Precipitated morphine withdrawal in rats as a tool in opiate research. Curr. Dev. Psychopharmacol. 4:1977;129-149.
2. Calabrese E., Baldwin L. Hormesis: U-shaped dose responses and their centrality in toxicology. Trends Pharmacol. Sci. 22:2001;285-291.
3. Cerletti C., Keinath S.H., Reidenberg M.M., Adler M.W. Chronic morphine administration: plasma levels and withdrawal syndrome in rats. Pharmacol. Biochem. Behav. 4:1976;323-327.
4. Chen H.V., Pellegrini J.W., Aggarwal S.K., Lei S.Z., Warach S., Jensen F.E.et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12:1992;4427-4438.
5. Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann. Intern. Med. 114:1991;667-677.
6. Elliott K., Hynansky A., Inturrisi C.E. Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain. 59:1994;361-368.
7. Gellert V.F., Holtzman S.G. Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J. Pharmacol. Exp. Ther. 205:1978;536-546.
8. Gutstein H. Potential physiologic mechanism for ketamine-induced emergence delirium. Anesthesiology. 84:1996;474.
9. Gutstein H., Trujillo K. MK-801 inhibits the development of morphine tolerance at spinal sites. Brain Res. 626:1993;332-334.
10. Gutstein H., Trujillo K., Akil H. Does chronic nociceptive stimulation alter the development of morphine tolerance? Brain Res. 680:1995;173-179.
11. Lei S.Z., Pan Z., Aggarwal S.K., Chen H.V., Hartman J., Sucher N.J.et al. Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex. Neuron. 6:1992;1087-1099.
12. Lipton S.A. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci. 16:1993;527-532.
13. Lipton S.A., Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330:1994;613-622.
14. Lipton S.A., Choi Y., Pan Z., Lei S.Z., Chen H.V., Sucher N.J.et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related netroso-compounds. Nature. 364:1993;626-632.
15. Mao J., Price D., Mayer D. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain. 62:1995;259-274.
16. Marek P., Ben-Eliyahu S., Gold M., Liebeskind J.C. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res. 547:1991;77-81.
17. Munzel T., Giaid A., Kurz S., Stewart D.J., Harrison D.G. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc. Natl. Acad. Sci. USA. 92:1995;5244-5248.
18. Needleman P. Tolerance to the vascular effects of glyceryl trinitrate. J. Pharmacol. Exp. Ther. 171:1970;98-102.
19. Olney J., Labruyere J., Wand G., Wozniak D., Price M., Sesma M. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 254:1991;1515-1518.
20. Parker J. Nitrate tolerance in angina pectoris. Cardiovasc. Drugs Ther. 2:1989;823-829.
21. Shlevin H.H. Animal pharmacology of nitroglycerin. Life Sci. 30:1982;1233-1246.
22. Sindrup S., Jensen T. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 83:1999;389-400.
23. Stamler J.S., Singel D.J., Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science. 258:1992;1898-1902.
24. Tiseo P.J., Inturrisi C.E. Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614. J. Pharmacol. Exp. Ther. 264:1993;1090-1096.
25. Tiseo P.J., Cheng J., Pasternak G.W., Inturrisi C.E. Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: assessment of opioid receptor changes. J. Pharmacol. Exp. Ther. 268:1993;195.
26. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 251:1991;85-87.
27. Trujillo K.A., Akil H. The NMDA receptor antagonist MK-801 increases morphine catalepsy and lethality. Pharmacol. Biochem. Behav. 38:1991;673-675.
28. Trujillo K.A., Akil H. Opiate tolerance and dependence: recent findings and synthesis. New Biol. 3:1991;915-923.
29. Trujillo K.A., Akil H. Excitatory amino acids and drugs of abuse: a role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence. Drug Alcohol Depend. 38:1995;139-154.
30. Yoburn B.C., Chen J., Huang T., Inturrisi C.E. Pharmacokinetics and pharmacodynamics of subcutaneous morphine pellets in the rat. J. Pharmacol. Exp. Ther. 235:1985;282-286.